| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 425.897 | 270.568 | 264.988 | 313.041 | 274.063 | 239.548 | 374.508 | 306.789 | 268.321 | 241.772 |
| Total Income - EUR | 397.712 | 274.302 | 275.291 | 323.602 | 275.228 | 246.606 | 384.091 | 321.413 | 276.916 | 247.577 |
| Total Expenses - EUR | 368.480 | 287.166 | 271.684 | 310.955 | 277.284 | 218.949 | 346.880 | 327.262 | 308.116 | 297.523 |
| Gross Profit/Loss - EUR | 29.232 | -12.864 | 3.607 | 12.646 | -2.056 | 27.657 | 37.211 | -5.849 | -31.200 | -49.946 |
| Net Profit/Loss - EUR | 22.542 | -13.375 | 580 | 9.462 | -4.915 | 25.197 | 33.369 | -9.081 | -33.975 | -57.341 |
| Employees | 8 | 8 | 8 | 7 | 6 | 6 | 5 | 4 | 4 | 4 |
Check the financial reports for the company - Algomed Group Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 31.308 | 18.624 | 16.303 | 10.639 | 7.664 | 6.135 | 9.142 | 26.760 | 48.716 | 38.095 |
| Current Assets | 334.354 | 323.090 | 314.835 | 349.720 | 306.236 | 315.509 | 353.234 | 319.104 | 285.198 | 263.085 |
| Inventories | 138.933 | 172.660 | 167.001 | 180.549 | 184.779 | 196.035 | 226.870 | 250.501 | 228.344 | 211.376 |
| Receivables | 119.059 | 116.408 | 114.833 | 87.216 | 113.183 | 84.621 | 96.305 | 61.172 | 54.657 | 46.606 |
| Cash | 76.361 | 34.023 | 33.001 | 81.956 | 8.273 | 34.854 | 30.059 | 7.432 | 2.196 | 5.103 |
| Shareholders Funds | 294.999 | 278.615 | 274.481 | 278.906 | 268.589 | 288.694 | 315.661 | 307.559 | 272.651 | 213.786 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 70.671 | 63.099 | 56.657 | 81.454 | 45.310 | 32.950 | 46.714 | 38.305 | 61.263 | 87.393 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4690 - 4690" | |||||||||
| CAEN Financial Year |
4690
|
|||||||||
Comments - Algomed Group Srl